scholarly journals Plasma Big Endothelin-1 Level and the Severity of New-onset Stable Coronary Artery Disease

2015 ◽  
Vol 22 (2) ◽  
pp. 126-135 ◽  
Author(s):  
Juan Chen ◽  
Man-Hua Chen ◽  
Yuan-Lin Guo ◽  
Cheng-Gang Zhu ◽  
Rui-Xia Xu ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Stable Coronary Artery Disease ◽  
Endothelin 1 ◽  
Artery Disease ◽  
New Onset

scholarly journals Diabetes, Glycemic Control, and New-Onset Heart Failure in Patients With Stable Coronary Artery Disease: Data from the Heart and Soul Study

Diabetes Care ◽  
2010 ◽  
Vol 33 (9) ◽  
pp. 2084-2089 ◽  
Author(s):  
J. P. van Melle ◽  
M. Bot ◽  
P. de Jonge ◽  
R. A. de Boer ◽  
D. J. van Veldhuisen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Glycemic Control ◽  
Stable Coronary Artery Disease ◽  
Artery Disease ◽  
New Onset

scholarly journals Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial

2020 ◽  
Author(s):  
David Corcoran ◽  
Aleksandra Radjenovic ◽  
Ify R Mordi ◽  
Sheraz A Nazir ◽  
Simon J Wilson ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Myocardial Perfusion ◽  
Cystatin C ◽  
Stable Coronary Artery Disease ◽  
Stress Perfusion ◽  
Controlled Study ◽  
Endothelin 1 ◽  
Artery Disease

Abstract Aims The effects of serelaxin, a recombinant form of human relaxin-2 peptide, on vascular function in the coronary microvascular and systemic macrovascular circulation remain largely unknown. This mechanistic, clinical study assessed the effects of serelaxin on myocardial perfusion, aortic stiffness, and safety in patients with stable coronary artery disease (CAD). Methods and results In this multicentre, double-blind, parallel-group, placebo-controlled study, 58 patients were randomized 1:1 to 48 h intravenous infusion of serelaxin (30 µg/kg/day) or matching placebo. The primary endpoints were change from baseline to 47 h post-initiation of the infusion in global myocardial perfusion reserve (MPR) assessed using adenosine stress perfusion cardiac magnetic resonance imaging, and applanation tonometry-derived augmentation index (AIx). Secondary endpoints were: change from baseline in AIx and pulse wave velocity, assessed at 47 h, Day 30, and Day 180; aortic distensibility at 47 h; pharmacokinetics and safety. Exploratory endpoints were the effect on cardiorenal biomarkers [N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), endothelin-1, and cystatin C]. Of 58 patients, 51 were included in the primary analysis (serelaxin, n = 25; placebo, n = 26). After 2 and 6 h of serelaxin infusion, mean placebo-corrected blood pressure reductions of −9.6 mmHg (P = 0.01) and −13.5 mmHg (P = 0.0003) for systolic blood pressure and −5.2 mmHg (P = 0.02) and −8.4 mmHg (P = 0.001) for diastolic blood pressure occurred. There were no between-group differences from baseline to 47 h in global MPR (−0.24 vs. −0.13, P = 0.44) or AIx (3.49% vs. 0.04%, P = 0.21) with serelaxin compared with placebo. Endothelin-1 and cystatin C levels decreased from baseline in the serelaxin group, and there were no clinically relevant changes observed with serelaxin for NT-proBNP or hsTnT. Similar numbers of serious adverse events were observed in both groups (serelaxin, n = 5; placebo, n = 7) to 180-day follow-up. Conclusion In patients with stable CAD, 48 h intravenous serelaxin reduced blood pressure but did not alter myocardial perfusion.

Sign in / Sign up

Export Citation Format

Share Document